From: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
Age
KPS
PR+CR
Number of prior chemotherapies
0
1
2
≥ 3
Mean
41
84
10%
2.5%
52%
34%
9%
SEM
0.7
0.5
2.2
1.8
6.0
4.7
2.3
Group ranges
36–47
80–88
0–33
0–24
10–100
0–69
0–26